Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.
Sox9 Protein Enables Molecular Time Travel That Can Lead to Colorectal Cancer
April 5th 2023Research from Dana-Farber Cancer Institute looks at what happens before the emergence of mutations that interrupt cellular differentiation in colorectal cancer and finds not only evidence of fetal reprogramming that can initiate cancer, but also a protein, Sox9, that fuels that reprogramming.
Novobiocin Attacks BRCA-Mutated Cancer Cells from Within and Without, Study Shows
March 31st 2023As the first clinical trial of the drug novobiocin is about to open for patients with cancers carrying BRCA gene mutations, new research at Dana-Farber Cancer Institute shows the drug poses a double threat to tumor cells.
FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer
March 20th 2023Dr Tolaney discusses the FDA approval of sacituzumab govitecan in patients with unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer; key data from the TROPiCS-02 trial; and how this agent can fulfill unmet needs for this patient population.
Maintenance Avelumab Plus Lurbinectedin Under Investigation in Metastatic Urothelial Carcinoma
Investigators are assessing the combination of avelumab and lurbinectedin as maintenance therapy for patients with metastatic urothelial carcinoma who achieve a response or stable disease following first-line, platinum-based chemotherapy in a single-arm phase 2 trial.
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
March 13th 2023Despite a perhaps overwhelming number of combination regimens available for use in the frontline setting for patients with renal cell carcinoma, treatment decisions can still largely boil down to a patient’s risk status. For second-line therapy, investigators are looking to contemporary trials for guidance.
New Generation of TKIs Challenge Standards of Care in Newly Diagnosed Ph+ ALL
March 7th 2023The advent of effective first-generation TKIs has allowed for improvements among patients with Philadelphia chromosome–positive disease, which is traditionally associated with a poor prognosis, as it generally does not respond to conventional chemotherapy options.
ADI-001 Produces Responses, Favorable Safety in Relapsed/Refractory B-Cell NHL
ADI-001, a first-in-class, allogeneic gamma delta1 CAR T-cell therapy, elicited responses and demonstrated a favorable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Dana-Farber Research Supports FDA Approval of New Therapy for Metastatic Breast Cancer
February 16th 2023Sacituzumab govitecan, a novel antibody drug-conjugate therapy has been granted accelerated approved by the U.S. Food and Drug Administration for the treatment of metastatic HR+, HER2- breast cancer.
Dr. Choudhury on The Need for Biomarkers to Predict Benefit With PARP Inhibitors in mCRPC
February 14th 2023Atish D. Choudhury, MD, PhD, discusses the need for expanded genomic profiling and additional biomarkers to better predict which patients with metastatic castration-resistant prostate cancer could benefit from treatment with PARP inhibitor–based combinations.
Immunotherapy Propels Urothelial Carcinoma Treatment Advances
February 2nd 2023Stephanie A. Berg, DO, highlights ongoing urothelial cancer clinical trials; the role of single-agent immunotherapy and combinations in this disease; and the importance of future research that prioritizes and guides individualized patient care.